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Abstract
Background: Although methadone has been used for the maintenance treatment of opioid dependence for
decades, it was not introduced in China or Taiwan until 2000s. Methadone-drug interactions (MDIs) have been
shown to cause many adverse effects. However, such effects have not been scrutinized in the ethnic Chinese
community.
Methods: The study was performed in two major hospitals in southern Taiwan. A total of 178 non-HIV patients
aged ≥ 20 years who had participated in the Methadone Maintenance Treatment Program (MMTP) ≥ 1 month
were recruited. An MDI is defined as concurrent use of drug(s) with methadone that may result in an increase or
decrease of effectiveness and/or adverse effect of methadone. To determine the prevalence and clinical
characteristics of MDIs, credible data sources, including the National Health Insurance (NHI) database, face-to-face
interviews, medical records, and methadone computer databases, were linked for analysis. Socio-demographic and
clinical factors associated with MDIs and co-medications were also examined.
Results: 128 (72%) MMTP patients took at least one medication. Clinically significant MDIs included withdrawal
symptoms, which were found among MMTP patients co-administered with buprenorphine or tramadol; severe QTc
prolongation effect, which might be associated with use of haloperidol or droperidol; and additive CNS and
respiratory depression, which could result from use of methadone in combination with chlorpromazine or
thioridazine. Past amphetamine use, co-infection with hepatitis C, and a longer retention in the MMTP were
associated with increased odds of co-medication. Among patients with co-medication use, significant correlates of
MDIs included the male gender and length of co-medication in the MMTP.
Conclusions: The results demonstrate clinical evidence of significant MDIs among MMTP patients. Clinicians should
check the past medical history of MMTP clients carefully before prescribing medicines. Because combinations of
methadone with other psychotropic or opioid medications can affect treatment outcomes or precipitate
withdrawal symptoms, clinicians should be cautious when prescribing these medications to MMTP patients and
monitor the therapeutic effects and adverse drug reactions. Although it is difficult to interconnect medical data
from different sources for the sake of privacy protection, the incumbent agency should develop pharmacovigilant
measures to prevent the MDIs from occurring. Physicians are also advised to check more carefully on the
medication history of their MMTP patients.
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Methadone, a long-acting synthetic opioid originally
developed for pain control, is now mainly used for the
treatment of opioid dependence [1]. The Methadone
Maintenance Treatment Program (MMTP), by providing
adequate oral methadone doses to heroin-dependent
patients once a day, aims to reduce cravings for heroin,
injecting drug use behavior, risks of HIV or hepatitis
infection, criminal activity, and eventually to improve
their quality of life [2-6]. However, several factors,
including methadone dosage [7-10], adverse drug reac-
tions (ADRs), and methadone-drug interactions (MDIs)
[11,12], can affect treatment compliance. Receipt of low
or inadequate doses of methadone has been associated
with higher rates of withdrawal symptoms and dropout
rates [13,14]. In contrast, overmedication may cause
s o m n o l e n c e ,i t c h i n g ,h y p o t ension, or even respiratory
depression [15]. Moreover, methadone-associated ADRs,
including constipation, nausea, erectile dysfunction [16],
sleeping disorders, menstrual cycle irregularities [17],
and in severe cases, disturbance of patients’ daily lives,
are often observed. The most dangerous side effect of
methadone is torsade de pointes (TdP) [18-22], which
may threaten a patient’s life. MDIs can either increase
[23] or decrease [24] serum methadone levels, leading to
treatment failure or even death [19,25]. Therefore,
proper methadone dose adjustment and therapeutic
drug monitoring should be handled with caution when
MMTP patients also have received other medicines that
could yield TdP or interfere with the activities of cyto-
chrome P 450 (CYP450) enzymes, such as 3A4 [26], 2B6
[26,27], 2C19 [27] or 2D6 [28].
Previous studies have revealed that mortality of
MMTP patients due to methadone overdose is fre-
quently associated with drug combinations, such as ben-
zodiazepines (59%), opiates (86%), or cocaine (34%) [29].
Case reports have also described methadone-associated
death due to co-administration of methadone with
temazepam and amitriptyline [18], or with sodium
valproate, amitriptyline, and fluoxetine [19]. In addition,
methadone-antiretroviral agent interactions have been
investigated. For instance, nevirapine can significantly
reduce the methadone plasma concentration [30]. QT
prolongation has been observed in patients who take
methadone with abacavir, nevirapine, tenofovir, and vor-
iconazole [31]. However, most patients participated in
these studies were from Western societies and, there-
fore, are limited to Caucasian or African origins [32-35].
In addition, many, if not most, studies focused on the
interactions of anti-retroviral agents and methadone
among HIV patients in MMTP [24,29-31,34-36].
Furthermore, these studies were mostly based on
reviews of medical or pharmacy records, and therefore
may be limited by incomplete information and recall
bias. Because MMTP was not implemented in China or
Taiwan until 2004 and 2006, respectively, few, if any,
studies have been conducted to assess the prevalence of
MDIs in non-HIV MMTP patients of Chinese origin.
In Taiwan, the prevalence of IDUs among all addic-
tion treatment admissions increased from 34.7% in 2000
to 63.9% in 2004, and the percentage of needle-sharing
among IDUs increased from 4.0% in 2000 to 15% in
2004 [37]. To address the escalating IDU and HIV infec-
tions through needle-sharing, the first MMTPs were
implemented in July 2006 [38,39]. Because of this new
measure, it is especially important for medical profes-
sionals to understand the comprehensive effects of
MDIs among MMTP patients to inform treatment plan-
ning and care management.
The National Health Insurance (NHI) program, a
national universal health insurance program with a cov-
erage rate of over 99% for all citizens in Taiwan, pro-
vides general medical and pharmacy records for all
patients. However, the MMTP in Taiwan is a separate
treatment entity from general medical practice. Unlike
the general medical care that is covered by the national
health insurance and eligible to all citizens, the MMTP
is subsidized from the budget of Taiwan Centers for
Disease Control (TCDC) and applied only to patients
enrolled in the program. The teamwork of MMTP
includes psychiatrists with certified addiction treatment
specialty, nurses and case managers who assist the
patients in finding the social cares for clients or moni-
toring the days of attendance at MMTP, and pharma-
cists who dispense methadone and check whether
patients have taken the medicines. The MMTP also pro-
vides educational programs for specific patients who
were under the conditions of deferred prosecution.
In order to prevent MMTP patients from the potential
danger of clinically significant MDIs, it is important to
identify the prevalence and relevance of MDIs with
clinically adverse effects. The clinical evidence will assist
TCDC in revising guidelines to improve the drug safety
among MMTP clients. Therefore, we utilized multiple
sources of available data (NHI database, face-to-face
interviews, medical records, and methadone computer
databases) to investigate the prevalence and clinical rele-
vance of MDIs in non-HIV patients.
Methods
Data sources and study sample
This study was conducted from February 2010 to Octo-
ber 2010 at Jianan Mental Hospital of the Department
of Health, the first mental hospital to implement a
MMTP, and Chung-Ho Memorial Hospital of Kaoh-
siung Medical University, a major medical center in
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with non-HIV infections (confirmed by medical records)
aged ≥ 20 years who had participated in the MMTP ≥ 1
month were recruited. An MDI was defined as concur-
rent use of drug(s) with methadone that may result in
an increase or decrease of effectiveness and/or adverse
effect of methadone. Medical expenses of HIV-positive
patients in Taiwan are covered by the national health
insurance program and exempt from medical co-pay-
ments to encourage their use of treatments. They hold a
medical registration card different from non-HIV
patients for medical exemption when seeking treat-
ments. For reasons of confidentiality and possible sam-
pling bias, HIV-positive patients were excluded in this
study.
All information was kept strictly confidential and used
for research proposes only. Participants received an
indemnity of about 8.5 US dollars for participating in
this study. The study was approved by the Institutional
Review Boards of Jianan Mental Hospital (Approval No.
10-002) and Chung-Ho Memorial Hospital (Approval
No. KMUH-IRB-980429), and written informed consent
was obtained from all participants.
Socio-demographic characteristics and histories of
substance use were obtained from structured face-to-
face interviews, which were carried out in a private
space within the clinic away from other staff and
patients by a trained research assistant using a struc-
tured questionnaire. Socio-demographic characteristics
included age, sex, educational level (years of education
completed), current marital status, current employment
status, and sources of financial support. Substance use
referred to the use of cigarettes, alcohol, or betel quid,
while drug use included illicit use of heroin, ampheta-
mines (including methamphetamine), ketamine, MDMA
(3,4-methylenedioxymethamphetamine; ecstasy), or ben-
zodiazepines. The definition for use of these substances
was based on epidemiologicale v i d e n c ef r o mn a t i o n a l
surveys of substance use in Taiwan [40]. Data regarding
daily attendance records and methadone doses were
obtained from the computer database of the TCDC - a
centralized data depository for the national MMTP pro-
gram. Baseline demographic characteristics, admission
date to the MMTP, and data of hepatitis, including
hepatitis B (HBV) or hepatitis C (HCV), as defined by a
patient’s serological blood test with the presence of
hepatitis B surface antigen (HBsAg) or detected antibo-
dies to HCV, respectively, were derived from medical
records.
Prescription data
In March 1995, the NHI was initiated as a national uni-
versal health insurance program for all citizens in Tai-
wan; by December 2010, up to 99.5% of the citizens in
Taiwan had participated in the program. All inpatient
and outpatient prescription data from all registered par-
ticipants in the NHI data depository from the time that
MMTP was initiated in July 2007 to August 2010 were
available for research.
Methadone-drug interactions (MDIs) data
The severity levels of MDIs, based on Micromedex
®
[41], Lexi-Interact™ [42] and published studies [43,44],
are summarized in Table 1. In Micromedex
®,i ti sc a t e -
gorized into five levels by the severity, namely, contrain-
dicated, major, moderate, minor and unknown, while
t h es e v e r i t yo fD D I si nL e x i - I n t e r a c t ™ is categorized
into three levels, i.e., major, moderate, and minor.
Because some MDIs were not listed in these two data-
bases, we also incorporated the severity of MDIs from
published reports [43,44].
Therefore, the criteria for the severity of an interaction
is integrated and defined as: level 1: drugs should not be
co-administered or major MDIs should be considered,
as stated in Micromedex
® [41] and Lexi-Interact™ [42],
because they may lead to serious ADRs or precipitate
opioid withdrawal; level 2: drugs may have potential
interactions that can modify the dosage, and patients
should be monitored closely to minimize adverse clinical
consequences; and level 3: minor or unknown interac-
tions. The patients’ clinical information, including data
collected from medical records, NHI and CDC-MMTP,
was connected by personal ID with a written informed
consent of the patient. These three databases were
incorporated by Microsoft Access 2003. To link the data
with the Anatomical Therapeutic Chemical (ATC) codes
in the NHI dataset, drugs listed in Table 1 were
recorded on the basis of the ATC classification system.
This connection was used to screen each patient’s medi-
cation profile from the time of MMTP initiation to
August 2010. When an MDI was identified, the interact-
ing drug, the severity level, and the pharmacological
class were recorded.
Statistical analyses
Descriptive statistics were performed to examine the
interacting drugs and severity levels. Baseline socio-
demographic characteristics, duration of membership in
the MMTP, hepatitis data, substance use status, as well
as data on daily methadone attendance records and
methadone doses, were compared using the Mann-
Whitney U test for continuous variables and the Chi-
square test or Fisher’s exact test for categorical variables
to account for the small sample size. Logistic regression
was conducted to explore associations of potentially pre-
dictive variables (socio-demographics, duration of mem-
bership in the MMTP, clinical data, and substance use
characteristics) with co-medication and MDIs.
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version 9.0 (SAS Institute, Cary, NC, USA); p-values were
two-sided with statistical significance set at p < 0.05.
Results
Selected characteristics of MMTP patients
The 178 participants included 156 males and 22 females,
with a mean age of 39.5 ± 7.1 years (range: 25-59 years)
and a mean weight of 68.8 ± 12.8 kg (40-118 kg). The
mean methadone daily maintenance dose was 50.8 ±
30.5 mg (5-250 mg/d). The prevalence of HBV and
HCV was 18.5% and 89.9%, respectively. The drug inter-
action group had a higher retention in the MMTP than
those not in the drug interaction group (22.8 vs. 17.7
months, P = 0.04, df = 126; Table 2); there were no sig-
nificant differences in the other characteristics by drug
interaction status (presence or absence of MDIs).
Methadone-drug interactions
Overall, there were 7,239 co-medication data that 72% (n
= 128) of MMTP patients were on at least one medica-
tion. Comparatively common medications co-existing
with methadone were acetaminophen (7%), flunitrazepam
(5%), diclofenac (2.5%), zolpidem (2.4%), and trazodone
(2.3%). Twenty-six MMTP patients received pain medica-
tions, such as morphine, tramadol, buprenorphine, and
dextropropoxyphene. Thirty-six patients had co-occur-
ring anxiety/depressive disorders and were dependent on
benzodiazepine and benzo-like medications. Ten patients
had depressive disorders and took other antidepressants,
such as paroxetine, amitriptyline, imipramine, fluoxetine
and sertraline. There were a total of 699 MDI events, and
85 (48%) participants had at least 1 MDI (Figure 1).
Frequent therapeutic classes of MDIs are shown in Figure
2. The three most common MDIs pharmacological
classes were benzodiazepines (38.1%), opiate agonists and
partial agonists (29.7%), and H2-Blocker (18.8%). MDI
pharmacological classes belonging to the most dangerous
level (level 1) included opiate agonists and partial ago-
nists (8.6%), quinolones (6.3%), antiemetics (5.5%), tran-
quilizers (4.7%), central nervous system (CNS) agents
(3.1%), and analgesics and antipyretics (2.3%).
The five comparatively common MDIs (Table 3) included
alprazolam, cimetidine, dexamethasone, tramadol, and esta-
zolam. Interactions of benzodiazepines with methadone,
including alprazolam, estazolam, midazolam (2.7%), and
diazepam (2.1%), were also observed in some patients.
Level 1 MDIs may lead to serious ADRs or precipitate
opioid withdrawal [41,42]. The drugs resulting in level 1
MDIs with the most clinical significance are shown in
Table 4.
Of the identified MDIs, one significant and dangerous
side effect of methadone was a severe QTc prolongation
effect, which may be caused by haloperidol, ciprofloxa-
cin, droperidol, levofloxacin, or moxifloxacin. The MDIs
that could produce withdrawal symptoms were found in
MMTP patients co-administered with buprenorphine,
nalbuphine, or tramadol. Another hazardous effect was
additive CNS and respiratory depression, which could
result from methadone in combination with chlorpro-
mazine, prochlorperazine, and thioridazine.
Logistic regression of correlates of coadministration
Adjusted logistic regression analysis showed that past
amphetamine use (Adjusted Odds Ratio, AOR = 2.68, P
= 0.03), HCV infection (AOR = 6.68, P =0 . 0 1 ) ,H B V
Table 1 Severity levels of potential methadone-drug interactions (MDIs) based on Micromedex
® and Lexi-Interact™
interaction databases
Level Definition Drugs
1
a Drugs should not be coadministered as they might lead to
serious adverse events or precipitate opioid withdrawal
Buprenorphine, Tramadol, Nalbuphine, Naloxone, Naltrexone, Amiodarone,
Butorphanol, Ciprofloxacin, Chlorpromazine, Cisapride, Dezocine, Dofetilide,
Droperidol, Dronedarone, Fentanyl/Droperidol, Fluphenazine, Fospropofol,
Gatifloxacin, Halofantrine, Haloperidol, Ibutilide, Iloperidone, Lapatinib,
Levofloxacin, Mesoridazine, Moxifloxacin, Nalbuphine, Nilotinib, Paliperidone,
Perphenazine, Pimozide, Prochlorperazine, Promazine, Promethazine,
Quinidine, Quinine, Ranolazine, Sotalol, Sunitinb, Tapentadol, Telithromycin,
Tetrabenazine, Thiethylperazine, Thioridazine, Trifluoperazine, Vardenafil
2
b A potential interaction might modify the dosage; monitor
closely to minimize clinical consequences
Alprazolam, Estazolam, Flurazepam, Midazolam, Zopiclone, Clormethiazole,
Methylphenidate, Amitriptyline, Desipramine, Imipramine, Nortriptyline,
Protriptyline, Phenobarbital, Dexamethasone, Fusidic acid, Rifampicin,
Spironolactone, Diltiazem, Cimetidine, Dihydroergotamine, Fluconazole,
Ketoconazole, Erythromycin, Clarithromycin, Moclobemide, Fluoxetine,
Fluvoxamine, Paroxetine, Sertraline, Risperidone, Merperidine, Alfentanil,
Propoxyphene, Morphine, Carbamazepine, Phenytoin
3
c Minor or unknown interactions Dextromethorphan, Nifedipine, Diazepam, Metronidazole, Omeprazole,
Verapamil
aThe severity of the MDI was evaluated as a “contraindication” or “major” in Micromedex
® and Lexi-Interact™.
bA potential MDI may lower or raise serum
methadone levels, or drugs that may result in altered metabolism or unpredictable interactions in combination with methadone.
cA potential DDI may result in
minor or unknown interactions
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Page 4 of 12infection (AOR = 3.08, P = 0.05) and a longer duration
in the MMTP (AOR = 1.08, P < 0.0001) were associated
with increased odds of co-medication (Table 5) and that
being single or divorced/widowed were associated with
reduced odds of co-medication. Compared with male
patients (AOR = 0.63, P = 0.54), female patients were
associated with a higher risk of having a co-medication.
Logistic regression of correlates of MDIs
Stepwise logistic regression analysis was performed to
identify associations of predictive variables with MDIs.
Among patients with co-medication, adjusted analyses
showed that significant correlates for MDIs were male
(AOR = 4.88, P = 0.02), divorced/widowed (AOR = 2.24,
P = 0.19), and a longer length of co-medication in the
MMTP (AOR = 1.41, P = 0.002). However, current her-
oin use (AOR = 0.38, P = 0.04) was associated with
reduced odds of MDIs (Table 6).
Finally, a total of 6 ADR cases considered to have
potential MDIs of level 1 or 2 were identified from the
prescription database (Table 7). Two cases exhibited
symptoms of ADRs, such as depression and anxiety,
while combining methadone with tramadol. Another
two patients had received the 1
st generation antipsycho-
tics (e.g., chlorpromazine, thioridazine) for psychotic dis-
orders, and methadone-related ADRs were observed.
The last two cases appeared to have ADRs associated
with co-administration of methadone with dexametha-
sone, paroxetine, and ketoconazole, which are a
CYP3A4 strong inducer, a CYP2B6 moderate inhibitor,
and a CYP3A4 strong inhibitor, respectively.
Discussion
This was the first study that utilized multiple data
sources to systematically examine methadone-drug
interactions since the MMTP was implemented in
Table 2 Selected characteristics of co-medication subpopulation in the MMTP (128 patients) according to the presence
or absence of methadone-drug interactions (MDIs)
No interaction (n = 43) Drug interaction (n = 85) df P-value*
Mean age, (SD) 40.7 (6.8) 39.0 (7.4) 127 0.20
Male, n (%) 36 (83.7) 75 (88.2) 1 0.47
Mean body mass index, kg/m
2 (SD) 23.6 (3.3) 24.4 (3.9) 125 0.24
Education, n (%)
Less than high school 26 (60.5) 47 (55.3) 1 0.58
High school or above 17 (39.5) 38 (44.7)
Marital status, n (%)
Married or living with partner 13 (30.2) 27 (32.1) 2 0.69
Never married 24 (55.8) 41 (48.8)
Divorced/widowed 6 (14.0) 16 (19.1)
Employment, n (%)
Employed 30 (69.8) 55 (64.7) 1 0.57
Other 13 (30.2) 30 (35.3)
Current illicit drug use, n (%)
Heroin 22 (51.2) 30 (35.3) 1 0.08
Amphetamine(s) 1 (2.3) 3 (3.5) 1 0.99
Benzodiazepine(s) 7 (16.3) 14 (16.5) 1 0.98
Heroin use years, (SD) 9.5 (6.3) 7.6 (5.1) 119 0.11
Drug use in the past, n (%)
Heroin 43 (100) 85 (100) 1 –
Amphetamine(s) 26 (60.5) 56 (65.9) 1 0.55
MDMA 0 (0.0) 8 (9.4) 1 0.05
Ketamine 1 (2.3) 10 (11.8) 1 0.10
Other substance use, n (%)
Cigarettes 33 (83.7) 73 (85.9) 1 0.75
Alcohol 13 (30.2) 30 (35.3) 1 0.57
Betel quid 9 (20.9) 28 (32.9) 1 0.16
HCV coinfection, n (%) 42 (97.7) 79 (92.9) 1 0.42
HBV coinfection (HBsAg-positive), n (%) 9 (20.9) 18 (21.2) 1 0.97
Current methadone dose, mg (SD) 53.9 (25.7) 53.0 (29.7) 127 0.86
MMTP participation period, months (SD) 17.7 (12.5) 22.8 (13.8) 126 0.04*
*: statistical significance set at p < 0.05; Comparisons performed by the Mann-Whitney U test, Chi-square test or Fisher’s exact test when appropriate
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Page 5 of 12Figure 1 Prevalence of identified methadone-drug interactions (MDIs). Of the 178 participants, 48% (85/178) had at least one MDI event. A
total of 112 MDI events were classified as level 1, which indicated that drugs should not be coadministered with methadone, as they may lead
to serious adverse reactions or precipitate opioid withdrawal.
Figure 2 Occurrences of MDI among 85 out of the 178 MMTP patients. The bars show the percentages of patients taking different classes
of drugs and their corresponding pharmacological levels. *In Taiwan’s National Health Insurance (NHI) program, the pharmacologic classification
is based on the Anatomical Therapeutic Chemical (ATC) system in general. According to the ATC system, benzodiazepines are not included in
tranquilizers. Rather, they are included in anxiolytics. However, in the NHI program, benzodiazepines are counted separately from other
anxiolytics. Therefore, benzodiazepines, anxiolytics and tranquilizers are grouped separately.
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relates of comedication and MDIs among MMTP
patients. Owing to the high coverage rate of the NHI
(99%) in Taiwan, we were able to use the comprehen-
sively collected national clinical data to characterize
MDIs. Because the probability of MDIs and associated
morbidities increases with polydrug use and some MDIs
(e.g., an enhanced risk of overdose and poorer retention)
may intensify poor outcomes among MMTP patients, it
is clinically important to understand factors affecting
MDIs in order to inform early detection and prevention
of MDIs and to reduce adverse effects.
The majority of identified MDIs were associated with
benzodiazepines (38.1%), the most-prescribed therapeu-
tic drugs found in our participants. By comparison,
higher proportions of patients (51.5% and 73.0%) were
prescribed benzodiazepines in Switzerland [45] and Ger-
many [46], respectively. Previous studies have shown
that anxiety disorders were highly prevalent among
opioid-dependent MMTP patients [47-49], and therefore
many patients might have used benzodiazepines.
Furthermore, MMTP patients who use or abuse benzo-
diazepines can have a negative clinical effect because
they may have higher levels of addiction, use more illicit
Table 3 Twenty most frequently observed methadone-drug interactions (MDIs) among co-medication subpopulation in
the MMTP (128 patients)
Drugs that interact with
methadone
Level n (%) Mechanisms of MDI
Tramadol 1 42
(6.0)
Concomitant administration of methadone and tramadol may result in withdrawal symptoms;
methadone (moderate CYP 2D6 inhibitor) may decrease the metabolism of tramadol
Chlorpromazine 1 22
(3.1)
The concomitant use of methadone and chlorpromazine may cause additive CNS and respiratory
depression
Levofloxacin 1 16
(2.3)
Levofloxacin may increase the QTc prolonging effects of methadone
Prochlorperazine 1 12
(1.7)
The concomitant use of methadone and prochlorperazine may cause additive CNS and respiratory
depression
Alprazolam 2 99
(14.2)
Alprazolam may cause additive CNS depression
Cimetidine 2 84
(12.0)
Cimetidine (moderate CYP 3A4 and 2D6 inhibitor) may decrease the metabolism of methadone, raise
serum methadone concentrations and consequently increase the toxicity of methadone
Dexamethasone 2 48
(6.9)
Dexamethasone (moderate CYP 3A4 and 2B6 inducer) may increase the metabolism of methadone,
lower serum methadone concentrations and result in withdrawal symptoms
Estazolam 2 40
(5.7)
Estazolam may cause additive CNS depression
Fusidic acid 2 26
(3.7)
Fusidic acid may induce CYP enzyme
Pethidine 2 25
(3.6)
Interaction probably occurs due to additive opioid effects
Diltiazem 2 23
(3.3)
Diltiazem (moderate CYP 3A4 inhibitor) may decrease the metabolism of methadone, raise serum
methadone concentrations and consequently increase the toxicity of methadone
Carbamazepine 2 22
(3.1)
Carbamazepine (strong CYP 2B6 inducer) may increase the metabolism of methadone, lower serum
methadone concentrations and result in withdrawal symptoms
Imipramine 2 22
(3.1)
Imipramine (moderate CYP 2D6 inhibitor) may decrease the metabolism of methadone; combination
with methadone increases tricyclic antidepressant (TCA) toxicity
Risperidone 2 20
(2.9)
Risperidone accelerates methadone metabolism via interfering with absorption or displacing
methadone from plasma protein binding sites and results in withdrawal symptoms
Midazolam 2 19
(2.7)
Midazolam may cause additive CNS depression
Nifedipine 3 18
(2.6)
Methadone possibly increases the effects of nifidepine and increase the toxicity of nifedipine
Morphine 2 13
(1.9)
Interaction probably occurs due to additive opioid effects
Paroxetine 2 12
(1.7)
Paroxetine (moderate CYP 2B6 and 2D6 inhibitor) may decrease the metabolism of methadone and
raise serum methadone concentrations and consequently increase the toxicity of methadone
Erythromycin 2 12
(1.7)
Erythromycin (CYP 3A4 inhibitor) may decrease the metabolism of methadone, raise serum methadone
concentrations and consequently increase the toxicity of methadone
Dextromethorphan 3 25
(3.6)
Methadone may increase the levels/effects of dextromethorphan and increase the toxicity of
dextromethorphan
Diazepam 3 15
(2.1)
Diazepam may increase the methadone effects and consequently increase the toxicity of methadone
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blems, and have difficulty in retaining in treatment
[49,50]. Co-administration of benzodiazepines and
methadone may increase the risk of methadone over-
dose or even death [18,51,52]. In this study, the most
commonly prescribed benzodiazepine was alprazolam
(14.2%), which is also frequently reported to be involved
in methadone-related deaths [53,54].
Co-usage of opiate agonists and partial agonists
(29.7%) with methadone was the second common pat-
tern of use in this study. Combinations of methadone
with buprenorphine, pethidine, and tramadol were also
found in a study conducted in China [55], which are
consistent with the results of this study. In particular,
we found that morphine and pethidine were the most
frequently prescribed opiate agonists among partici-
pants. The reason for co-administration may be a result
of MMTP patients’ surgical use or seeking of additional
opiate analgesics to alleviate their craving. Patients in an
opioid maintenance treatment program can receive
buprenorphine or methadone, but normally they would
not be prescribed simultaneously. However, a MMTP
patient was prescribed with buprenorphine to relieve
pain after surgery (Table 4). In addition, Manchikanti et
al.[56] reported that a significantly increasing proportion
of patients receiving controlled substances were revealed
to use illicit drugs or other prescription opioids for non-
medical use. Therefore, clinicians should be cautious
when MMTP patients have received opiate agonists, as
they may enhance the risk of addictive effects or opioid
toxicity [57].
Clinically significant MDIs may share one of the three
common drug interaction mechanisms, which include (i)
increasing the QTc prolonging effect, the most serious
ADR of MDIs, which may consequently develop into
fatal TdP [19-21]; (ii) enhancing addictive CNS and
respiratory depression, which cause methadone-related
deaths [19]; (iii) triggering opioid withdrawal symptoms,
which may cause an increase in catecholamines plasma
concentrations, leading to the development of stress car-
diomyopathy [58] that, in turn, can cause death. Poten-
tial ADRs were also observed among patients who had
MDIs in this study. In addition to the three mechanisms
stated above, MDIs [27] caused by co-administering
Table 4 Drugs with Level-1 MDIs with the most clinical significance
Drugs Frequency Mechanisms of MDI
Tramadol 42 Concomitant administration of methadone and tramadol may result in withdrawal symptoms; methadone (moderate
CYP 2D6 inhibitor) may decrease the metabolism of tramadol
Chlorpromazine 22 The concomitant use of methadone and chlorpromazine may cause additive CNS and respiratory depression
Levofloxacin 16 Levofloxacin may increase the QTc prolonging effects of methadone
Prochlorperazine 12 The concomitant use of methadone and prochlorperazine may cause additive CNS and respiratory depression
Moxifloxacin 6 Moxifloxacin may increase the QTc prolonging effects of methadone
Ciprofloxacin 5 Ciprofloxacin may increase the QTc prolonging effects of methadone
Haloperidol 5 Haloperidol may increase the QTc prolonging effects of methadone
Buprenorphine 1 Concomitant administration of methadone and buprenorphine may result in withdrawal symptoms
Droperidol 1 Droperidol may increase the QTc prolonging effects of methadone
Nalbuphine 1 Concomitant administration of methadone and nalbuphine may result in withdrawal symptoms
Thioridazine 1 The concomitant use of methadone and thioridazine may cause additive CNS and respiratory depression
Table 5 Factors associated with comedication among the
total population in the MMTP (178 patients)
Characteristic Adjusted OR (95% CI) P-value
Age 1.02 (0.95 ~ 1.09) 0.61
Sex
Female 1.00 -
Male 0.63 (0.13 ~ 2.61) 0.54
Education
Less than high school 1.00 -
High school or above 2.42 (1.00 ~ 6.25) 0.06
Marital status
Married or living with partner 1.00 -
Never married 0.23 (0.06 ~ 0.72) 0.02*
Divorced/widowed 0.24 (0.06 ~ 0.89) 0.03*
Employment
Employed 1.00 -
Other 1.06 (0.41 ~ 2.66) 0.91
Drug use in the past
Amphetamine 2.68 (1.15 ~ 6.53) 0.03*
MDMA 0.19 (0.01 ~ 2.85) 0.26
Ketamine 4.84 (0.42 ~ 132.23) 0.25
Other use substances
Cigarettes 1.43 (0.46 ~ 4.32) 0.53
Alcohol 1.01 (0.42 ~ 2.45) 0.98
Betel quid 1.44 (0.50 ~ 4.36) 0.50
HBV coinfection 3.08 (1.03 ~ 10.77) 0.05
HCV coinfection 6.68 (1.56 ~ 31.06) 0.01*
MMTP participation period 1.08 (1.04 ~ 1.12) < 0.0001**
Logistic regression with all the other predictors entered into the model
OR = odds ratio
*: < 0.05; **: < 0.0001
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be carefully monitored and addressed. Moreover, studies
[27,59,60] have suggested that CYP2B6 plays an impor-
tant role in mediating methadone metabolism. Thus,
caution should be taken when combining methadone
with CYP2B6-inducing agents, such as carbamazepine,
phenytoin, rifampin, and phenobarbital, or with
CYP2B6-inhibiting agents, such as paroxetine, sertraline,
and desipramine. However, because of the difference in
the genetic polymorphism of CYP450 between Oriental
and Caucasian populations, the results may not be gen-
eralized to those of the US and Western Europe.
The identified correlates for co-medication included
use of amphetamines (e.g., methamphetamine) and co-
infection with HCV. Poly-pharmacy or poly- substance
use has been found to be common among MMTP
patients, especially use of amphetamines and benzodia-
zepines [61]. On the other hand, chronic HCV infection
may exhibit some symptoms, such as fatigue, nausea,
loss of appetite, muscle ache, flu-like symptoms, and
depression, or may even result in the development of
cirrhosis or liver cancer [62], which may increase use of
other illicit or non-prescribed drugs to relieve symptoms
(e.g., self-medication). For instance, we found that 89.9%
Table 6 Factors associated with methadone-drug interactions (MDIs) among the co-medication subpopulation in the
MMTP (128 patients)
Characteristics Adjusted OR (95% CI) P-value
Age 0.94 (0.88 ~ 0.99) 0.07
Sex
Female 1.00 -
Male 4.88 (1.25 ~ 20.17) 0.02*
Marital status
Married or living with partner 1.00 -
Divorced/widowed 2.24 (0.71 ~ 7.94) 0.19
Current illicit drug use
Heroin (yes vs. no) 0.38 (0.15 ~ 0.94) 0.04*
Number of comedications per MMTP participation months
a 1.41 (1.17 ~ 1.79) 0.002*
Stepwise logistic regression analysis was performed to identify associations of predictive variables
aThe number of comedications per MMTP participation months: MMT participation period for each patient divided by the total number of comedications
OR = odds ratio.
*: < 0.05; **: < 0.0001
Table 7 Suspected presence of Adverse Reactions (ADRs) in case reports resulting from methadone-drug interactions
(MDIs)
Case
no.
Suspected
Drugs
Mechanisms Description
1 Thioridazine Additive CNS and
respiratory depression
A 38-year-old man was diagnosed with drug-induced psychotic disorder with hallucinations
and started on thioridazine, flunitrazepam, and trihexyphenidyl for three months. He then
experienced anxiety causing hyperventilation, and was consequently treated with midazolam
and oxazolam.
2 Chlorpromazine Additive CNS and
respiratory depression
A 31-year-old woman was started on chlorpromazine for insomnia. After three months, she was
diagnosed with hyperventilation and tachycardia, which may have been a result of methadone
or a methadone-chlorpromazine interaction.
3 Tramadol May result in withdrawal
symptoms
A 48-year-old man was started on tramadol for a month. He then felt anxious, which may have
been caused by a methadone-tramadol interaction. Upon discontinuing tramadol, no other
symptoms related to anxiety persisted.
Dexamethasone CYP3A4 strong inducer This man was started on dexamethasone for intracranial injury. After coadministering
methadone with dexamethasone for a month, he started to feel anxious.
4 Tramadol May result in withdrawal
symptoms
A 48-year-old man was prescribed tramadol for a month for fractures of the tibia and fibula.
Then, he developed a depressive mood, which may be owing to a methadone-tramadol
interaction.
5 Paroxetine CYP2B6 moderate
inhibitor
A 38-year-old man was diagnosed with depression and started on paroxetine for several
months. When methadone was coadministered with paroxetine, an anxious feeling persisted.
6 Ketoconazole CYP3A4 strong inhibitor A 41-year-old man’s foot was infected with mycoses and was started on ketoconazole for two
months. He was then diagnosed with angina pectoris, which may be due to a methadone-
ketoconazole interaction. Upon stopping ketoconazole, he did not experience any symptoms
related to angina.
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Page 9 of 12(160/178) of patients were infected with HCV, but only
3.4% (6/178) patients received HCV therapy (ribavirin
plus peginterferon alpha 2A or 2B). A very low propor-
tion of HCV treatment has been observed in MMTP
patients [63].
T h ep r e v a l e n c eo fc i g a r e t t eu s ea m o n gM M T P
patients was threefold the rate than that in the general
population, and cigarette use increases the risk of mor-
bidity and mortality [64]. Smoking is also associated
with current mood or anxiety disorders among MMTP
patients, especially in women [65]. In line with the lit-
erature, some sedatives or antidepressants were found to
be frequently used in our MMTP patients, such as ser-
traline, paroxetine [23], fluoxetine, amitriptyline [66],
a n dz o l p i d e m[ 6 6 ] ,w h i c hm ay affect the serum metha-
done concentration due to the involvement of the same
CYP450 enzymes with methadone metabolism. Further,
methadone interacts not only with the above drugs, but
also with nicotine, which may increase euphoria and
decrease restlessness, irritability, and depression [67].
Identification of clinical factors associated with MDIs
will assist physicians in eliminating or preventing poten-
tial risks. Male patients were strongly associated with
having MDIs (AOR = 4.88, P = 0.02). Moreover, the
odds of MDIs in patients with co-medications per
MMTP participation months were 1.41 times greater
than those without co-medications. Younger age was
weakly associated with decreased odds of MDIs by 0.94.
This can be explained in part by their lower rate of car-
diovascular diseases, which are associated with serious
ADRs (i.e., TdP) and are more prevalent among older
patients [68]. In this study, some common ADRs, such
as sweating, constipation, and insomnia, were noticed
during the treatment, though two patients had been
diagnosed with arrhythmia before this study, and one
patient had tarchycardia related to a suspected metha-
done- chlorpromazine interaction in this study. There-
fore, the prescription of medications that could induce
QT interval prolongation should be avoided in these
patients.
These results should be interpreted within the context
of the following limitations. First, this study was con-
ducted in southern Taiwan, and the results may not be
generalized to other regions in Taiwan. Because MMTP
patients may have different attitudes towards or habits
related to the treatment of diseases, some may use over-
the-counter (OTC) medications or Chinese herbal medi-
cines to alleviate symptoms. Second, because OTC med-
ications or Chinese herbal medicines are not covered by
the national health insurance program, the interaction
events resulting from OTC drugs-methadone or Chinese
herbal medicines-methadone may be underestimated
among MMTP patients who used additional OTC medi-
cations or Chinese herbal medicines. Moreover,
flunitrazepam, a benzodiazepines drug, was not included
in Micromedex
®[41] or Lexi-Interact™[42]. Hence, we
have not included this potential MDI in our list, and
such MDIs may be underestimated. However, it should
be noted that this kind of MDI may often be missed by
clinicians. Finally, our definitions for
MDIs depend on the level of completeness of the
available data banks (Micromedex
® and Lexi-Interact™).
To minimize bias, several well-documented databases
were also integrated in this study.
In conclusion, to improve clinical care and prevent
MDIs and MDI-related deaths, it is important that fre-
quent MDIs and their characteristics among MMTP
patients are identified and incorporated into care man-
agement. The present study utilized multiple data
sources (a national medical database, face-to-face inter-
views, medical records, and methadone computer data-
bases) to systematically characterize MDIs to help
inform clinical care. The results demonstrate clinical
evidence of significant MDIs (quinolones, benzodiaze-
pines, opiate agonists and partial agonists) among
MMTP patients in Taiwan. Given the potential adverse
effects from co-usage of methadone with benzodiaze-
pines or opiate partial agonists, clinicians should be cau-
tious in prescribing these medications to MMTP
patients and incorporate clinical monitoring of potential
ADRs of MDIs into treatment plans.
To protect the privacy of MMTP patients, it is diffi-
cult to interconnect medical data from different sources.
However, the incumbent agency should be responsible
for developing pharmacovigilant measures to improve
the quality of essential MMTP care services and to pre-
vent the MDIs from occurring. Meanwhile, it is recom-
mended that physicians should check the past and
current medication history of MMTP patients, especially
who have ever used quinolones, benzodiazepines, opiate
agonists and partial agonists. From the findings in this
paper, it is desperately needed to provide proper train-
ing to prescribing clinicians/providers in MMTPs and
generalists in primary care to pay special attention when
prescribing methadone and concomitant medications for
co-occurring disorders. At the same time, it is also
imperative to educate patients and their families of the
danger of methadone drug interactions and methadone
overdose.
In the future, it will be of interest to look into the
association between the patients’ doses and genetic poly-
morphism that affects methadone metabolism, as well as
their impacts on the frequency or severity of MDIs.
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